OncoMatch/Clinical Trials/NCT06562920
Adebrelimab Combined With Chemotherapy and Concurrent SBRT for Neoadjuvant Treatment of Limited-stage Small Cell Lung Cancer
Is NCT06562920 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies adebrelimab and chemotherapy for efficacy and safety of neoadjuvant immunotherapy for small cell lung cancer.
Treatment: adebrelimab and chemotherapy — To explore the effectiveness and safety of adebrelimab combined with chemotherapy and concurrent SBRT for 3 cycles of neoadjuvant treatment followed by surgery in T1-3N0-1M0 limited-stage SCLC
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Small Cell Lung Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: anti-tumor treatment
No previous anti-tumor treatment such as surgery, radiotherapy, chemotherapy, immunotherapy, etc. related to small cell lung cancer
Cannot have received: immune checkpoint inhibitor (PD-1 inhibitor, PD-L1 inhibitor)
Previously used immune checkpoint inhibitors such as PD-1/PD-L1 inhibitors
Cannot have received: anti-tumor vaccine or immunostimulatory therapy (interferon, interleukin, thymosin, immune cell therapy)
Subjects who have been treated with anti-tumor vaccines or other anti-tumor drugs with immunostimulatory effects (interferon, interleukin, thymosin, immune cell therapy, etc.) within 1 month before the first medication
Lab requirements
Blood counts
ANC ≥1.5×10^9/L, platelets ≥100×10^9/L, hemoglobin ≥9 g/dl
Kidney function
serum creatinine ≤1.25x ULN or creatinine clearance ≥60 ml/min
Liver function
total bilirubin ≤1.5x ULN, AST and ALT ≤2.5x ULN
Cardiac function
LVEF ≥55%, no clear signs of heart failure, severe coronary artery stenosis, etc.; able to tolerate surgical treatment
Patients must have sufficient cardiopulmonary function: FEV1 and DLCO of patients are ≥50% of the predicted value, echocardiography indicates LVEF ≥55%, and no clear signs of heart failure, severe coronary artery stenosis, etc. are found in various tests. Cardiopulmonary function is assessed by surgeons to be able to tolerate surgical treatment; ...Bone marrow: absolute neutrophil count (ANC) ≥1.5× 10^9/L, platelets ≥100 × 10^9/L, hemoglobin ≥9 g/dl; ...Liver: total bilirubin ≤1.5 times the upper limit of normal, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 times the upper limit of normal; ...Kidney: serum creatinine ≤1.25 times the upper limit of normal or creatinine clearance (calculated by Cockcroft-Gault formula) ≥60 ml/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06562920 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages